<DOC>
	<DOCNO>NCT00517413</DOCNO>
	<brief_summary>This single arm study ass efficacy safety Mircera administer monthly , subcutaneously intravenously , maintenance hemoglobin level dialysis patient chronic renal anemia . Patients currently receive maintenance treatment epoetin alfa receive monthly injection Mircera start dose ( 120 , 200 360 microgram ) derive dose epoetin alfa receive week precede study start . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>LATINO Study : A Study Mircera Maintenance Treatment Dialysis Patients With Chronic Renal Anemia .</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; chronic renal anemia ; hemodialysis peritoneal dialysis , mode dialysis &gt; =3 month throughout screen period ; stable maintenance epoetin alfa therapy past 2 month . transfusion red blood cell previous 2 month ; poorly control hypertension require interruption epoetin alfa past 6 month ; acute chronic bleed previous 2 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>